Gene Disease Score gda Association Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.500 Biomarker BEFREE When compared to a reference of tumor tissue p16 IHC in 783 OPSCC patients, the clinic-HPV<sub>sero</sub> model incorporating a composite of 20 HPV serological antibodies (HPV<sub>sero</sub> ) and 4 clinical factors (c-index: 0.96) performed better than using HPV<sub>sero</sub> (c-index: 0.92) or HPV<sub>mi</sub> (c-index: 0.76) alone. 31269236

2020

Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.500 AlteredExpression BEFREE Mechanistically, these effects were mediated by attenuation of cell cycle progression, as Western blot analyses demonstrated upregulation of the tumor suppressor p21/CDKN2A and downregulation of the cell cycle regulator Cyclin D1 as well as reduced levels of phosphorylated ribosomal protein s6 (pRPS6) and retinoblastoma protein (pRb). 31018208

2020

Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.500 Biomarker BEFREE Tumor histology correlated well with p16 positivity (P<.001) and p16 IHC accurately predicted the presence of HPV in 25/26 (96%) cases. 31698006

2020

Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.500 Biomarker BEFREE DNA mismatch repair protein expression studies disclosed loss of nuclear immunostaining of MSH6 protein, pointing to the possibility of an underlying rare MSH6 variant of the Muir-Torre syndrome, not yet described in the ophthalmic literature. p16 nuclear positivity was also found in the tumor cells, indicating the possible role of high-risk human papillomavirus as an additional factor in the genesis of the tumor. 31557488

2020

Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.500 Biomarker BEFREE HPV 16 and/or 18 were detected in 156 (80%) tumors. p16 was positive in 186 (96%) carcinomas, but eight tumors (4%) were negative for p16 (seven squamous cell carcinomas, one adenocarcinoma); 5/8 caused by HPV 16 and/or 18. 31492932

2020

Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.500 AlteredExpression BEFREE Seven tissue microarrays were constructed. p16 protein expression was studied in 114 cases, of which 35/114 (30.7%) cases showed strong expression and the majority of them had ER-positive tumor (57.6%), and it was statistically significant (P < 0.0074). 31603125

2020

Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.500 Biomarker BEFREE Palbociclib is a CDK4 inhibitor with preclinical antitumor efficacy in tumors with P16/CDKN2A loss. 30979737

2019

Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.500 Biomarker BEFREE Furthermore, methylated RASSF1A and p14/ARF were associated with the grade of CRC but not associated with the age of patients, family history, or tumor location. 30989570

2019

Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.500 Biomarker BEFREE Additional FISH analyses detected a 9p21/CDKN2A double deletion, frequently reported in melanomas but not in nevi, in the tumor initially diagnosed as a Spitz nevus with a favor malignant p16-Ki-67-HMB45 score. 28362709

2019

Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.500 GeneticVariation BEFREE TERT promoter mutation, H3F3A mutation, CDKN2A loss) in this tumor group. 30298540

2019

Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.500 GeneticVariation BEFREE The total mutational burden was similar between human papillomavirus (HPV)-negative vs. positive tumors, although TP53, CDKN2A and CCND1 gene alterations occurred more frequently in HPV-negative tumors. 29747488

2019

Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.500 Biomarker BEFREE OncoScan analysis showed genetic changes that define field cancerization of the p16 negative tumor as revealed by mosaicism in both loss of heterozygosity and copy number alterations in cancer-associated genes located on 3p, 7p, 9p 11q, and 17p. 30552721

2019

Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.500 Biomarker BEFREE <i>K</i><sub>ep</sub> kurtosis was significantly higher in p16 tumors, and <i>V</i><sub>e</sub> min was significantly lower in p16 tumors compared to the p16 negative tumors. 30718984

2019

Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.500 AlteredExpression BEFREE The tumor expressed S100 and was negative for CD31, CD34, desmin, and smooth muscle actin.The expression of p16 was preserved. 30421509

2019

Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.500 GeneticVariation BEFREE Our study pointed out the utmost relevance of CDKN2A homozygous deletion as an adverse prognostic factor in the 2 broad categories of IDH-mutant gliomas stratified on 1p/19q codeletion and suggests that the grading of these tumors should be refined. 31832685

2019

Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.500 Biomarker BEFREE An Oncolytic Adenovirus Vector Expressing p14 FAST Protein Induces Widespread Syncytium Formation and Reduces Tumor Growth Rate <i>In Vivo</i>. 31193718

2019

Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.500 GeneticVariation BEFREE This study showed mutations in the tumor suppressor CDKN2A gene and the NRAS oncogene in 62.5% and 75%, respectively of the samples that had mutations in the ABCB5 gene. 30905807

2019

Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.500 AlteredExpression BEFREE A total of 28 studies with 2612 nasopharynx cancer patients were included in the meta-analysis. p16 protein expression was significantly associated with the risk, lymph node metastasis, TNM-stage (tumor-node-metastasis), distant metastasis, and T stage of nasopharynx cancer (Risk, OR = 17.82, 95% CI = 11.20-28.35; Lymph node metastasis, OR = 2.11, 95% CI = 1.42-3.14; TNM-stage, OR = 2.25, 95% CI = 1.54-3.28; Distant metastasis, OR = 3.43, 95% CI = 1.55-7.58; T-stage, OR = 1.72, 95% CI = 1.27-2.33). 30882625

2019

Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.500 AlteredExpression BEFREE The tumor suppressor gene FHIT is lowly expressed in breast cancer tissues and positively associated with the expression of the multi-tumor suppressor gene p16. 30941950

2019

Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.500 Biomarker BEFREE Distinct Roles of Direct Transduction Versus Exposure to the Tumor Secretome on Murine Endothelial Cells After Melanoma Gene Therapy with Interferon-β and p19Arf. 30848981

2019

Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.500 Biomarker BEFREE Intraperitoneal injection of bexarotene significantly decreased expressions of CCL22, CXCL5, CXCL10, and p19 in the tumor microenvironment. 31616630

2019

Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.500 AlteredExpression BEFREE Comparison of P16 expression in OSCC tumors with different degrees of promoter methylation further suggest the relationship of methylation rate and down-regulation of P16 expression. 30511108

2019

Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.500 Biomarker BEFREE Cancers rewire metabolism to facilitate proliferation; however, it is not well appreciated how this enables senescence bypass.Recent work by Buj et al. demonstrates that loss of the tumor suppressor p16 engages a mTORC1-dependent increase in nucleotide pools to override senescence. 31699584

2019

Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.500 Biomarker BEFREE The p16Ink4a plays an important role in tumor suppression, whereby its deletion, mutation, or epigenetic silencing is a frequently observed genetic alteration in prostate cancer. 30677079

2019

Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.500 GeneticVariation BEFREE The median tumor mutation burden for GBC patients was 5.4 (range: 0.8-36.74) mutations/Mb, and the most common mutations were in TP53 (73%), CDKN2A (25%) and PIK3CA (20%). 31700903

2019